About
About Trima
Experience the Power of Experience…
Founded over 80 years ago TRIMA is one of Israel’s most well-established pharmaceutical companies.
The Company specializes in the development, manufacturing, and marketing of generic drugs and other pharmaceutical products.
In addition to manufacturing and marketing over 60 products that were developed internally, we also import and market in Israel some 10 licensed products.
For licensed products Trima partners with various international companies. In doing so Trima leverages its intimate knowledge of the Israeli market and offers its partners unique benefits.
Our product portfolio of both manufactured and imported healthcare products range across multiple therapeutic areas and indications. Among others we are active in dermatology, respiratory, CNS, muscular-skeletal pains, allergy, cough and cold and much more.
Trima’s highly experienced R&D department develops generic drugs for both the Israeli and international markets.
At our EU-GMP manufacturing plan we manufacture a wide variety of Rx and OTC drugs in various forms, including tablets, capsules, gels, creams, powders, syrups and sprays.
In the Israeli market Trima has an active sales and marketing team responsible for promoting its branded generics and working with institutional buyers as well as with the private market.
Trima operates under the most stringent standards of the pharmaceutical industry, committing to uncompromising quality, the relentless pursuit of scientific excellence and the continued support of its partners and clients.
Our Vision
An evolving and progress seeking pharmaceutical company working on creativity for healthier tomorrow
Our History...
-
1935 -PALMED PALESTINE MEDICINE is established by Dr. Chaim Weizmann who later became the first President of Israel.
-
1962 -The company is purchased by Kibbutz Ma'abarot and renamed TRIMA - Israeli Pharmaceutical Products Ma’abrot Ltd.
-
1968 -Relocation of the plant to Ma'abarot industrial park, which remain the company's main manufacturing site.
-
1975 -the Company’s Headquarter and Packaging department move to a new site at Kibbutz Ma'abarot.
-
1998 -Motivan ltd. (a holding company) acquire 50% of the Company, following many years in which Trima served as developer and manufacturer for its pharmaceutical subsidiary, Unipharm Ltd.
-
2002 -Trima acquires a sophisticated analytical and R&D laboratory.
-
2018 -Kibbutz Ma'abarot buys back the shares sold to Motivan and regains 100% ownership of the Company.
Our Responsibility
We at TRIMA believe that engaging in not-for-profit activities demonstrates our commitment to Corporate Social Responsibility, which in turn benefits our employees the community we live in and the customers we serve.
As a pharmaceutical company we primarily support charitable organizations and activities in the healthcare space.
Our Commitment:
- Ensure our activities positively contribute to the local community.
- Engage with local organisations and representatives committed to making a difference.
- Support appropriate charitable organisations that share our aims and values, and provide support for them through charitable donations.
- Maintain a process by which employees can nominate other local charitable organisations for donations and support on an ad hoc basis.
- Identify opportunities for our products to be used to support charitable organisations.
Our Values
TRIMA is committed to excellence in execution, innovation in development and the highest quality of performance.
- Be Better : we strive for continuous improvement in all aspects.
- Be Team : we cultivate relationships through open communication and trust.
- Be Creative : we embrace new ideas and creative thinking.
- Be Ethical : we act with integrity, honesty and respect for others and our communities.
- Quality : We adhere to the highest standards of quality in everything we do.
- Be Socially Responsible : We are committed to supporting and contributing to the community we live in.
Our Team
-
Shmuel “Milky” Rubinstein - Chairman of the Board
Milky joined Trima’s board of directors in 2014 and serves as the Company’s chairman since 2018.
Milky also serves as a board member in various publicly trade and private companies including Clal Bio Technologies, Exalenz BioSicence, Medison Biotech, Univo Pharmaceuticals, and Tiltan Pharma (Chairman of the Board). He also serves as a consultant to BDO and Sol-Gel Pharma.
Milky held the position of the CEO of Taro Pharmaceuticals Industries Ltd. for over 20 years. Under His leadership, Taro became a public company trading on TASE and NASDAQ. During his time in Taro, the company turned into a multinational company with over 1000 employees worldwide and a turnover of $450 million.
On 2003, Milky received the Exceptional Industry Award from the Manufacturer’s Association of Israel.
Milky joined Trima’s board of directors in 2014 and serves as the Company’s chairman since 2018.
Milky also serves as a board member in various publicly trade and private companies including Clal Bio Technologies, Exalenz BioSicence, Medison Biotech, Univo Pharmaceuticals, and Tiltan Pharma (Chairman of the Board). He also serves as a consultant to BDO and Sol-Gel Pharma.
Milky held the position of the CEO of Taro Pharmaceuticals Industries Ltd. for over 20 years. Under His leadership, Taro became a public company trading on TASE and NASDAQ. During his time in Taro, the company turned into a multinational company with over 1000 employees worldwide and a turnover of $450 million.
On 2003, Milky received the Exceptional Industry Award from the Manufacturer’s Association of Israel.
-
Ran Vigdor - CEO
Ran became Chief Executive officer of TRIMA on January 1, 2019.
Ran has more than 15 years’ experience in the Pharmaceutical and Biotech industries, filling various senior leadership positions across a range of markets and disciplines.
Prior to joining TRIMA Ran held the position of CEO and Chairman of the Board of Tiltan Pharma, CEO of TCD Pharma, CEO and Member of the Board of Amadix, Business Development Director in CRB (an early stage VC) and Strategic Alliance Director in BioCancell Therapeutics (now – Anchiano Therapeutics, NASDAQ: ANCN).
Ran holds a LL.B in Law and a B.A. in Business Administration from the Hebrew University of Jerusalem, Israel and an M.B.A. from the IE Business School (Madrid, Spain).
Ran became Chief Executive officer of TRIMA on January 1, 2019.
Ran has more than 15 years’ experience in the Pharmaceutical and Biotech industries, filling various senior leadership positions across a range of markets and disciplines.
Prior to joining TRIMA Ran held the position of CEO and Chairman of the Board of Tiltan Pharma, CEO of TCD Pharma, CEO and Member of the Board of Amadix, Business Development Director in CRB (an early stage VC) and Strategic Alliance Director in BioCancell Therapeutics (now – Anchiano Therapeutics, NASDAQ: ANCN).
Ran holds a LL.B in Law and a B.A. in Business Administration from the Hebrew University of Jerusalem, Israel and an M.B.A. from the IE Business School (Madrid, Spain).
-
Yoav Rechav - COO and Deputy CEO
Yoav began his tenure at TRIMA in January 2019 and is responsible for Operations, Quality Assurance, QC labs and Engineering.
Prior to joining TRIMA, Yoav served as CEO of a start-up bio-pharmaceutical company in Caesarea, Israel, advancing a Pre-IND submission of the company’s technology as well as a round B $7.5M capital fund-raising. Prior to that, Yoav held various positions at Perrigo Israel Pharmaceuticals (PIL). He started his career as a QC manager at Agis Industries (later acquired by PIL), moved to head the Analytical R&D, head of R&D projects management of Chemagis, led all inter-company development programs, ran the PIL major expansion program (a ca. US$50 million, five-year program that encompassed over 12,000 square meters buildings for industrial and utilities purposes) and finally managed the operations of the PIL Yeroham site in Israel, with over $300 million annual supply chain to the US, EU and Israel.
Yoav earned his B.Sc. in Chemistry and M.Sc. in Organic Chemistry from the Hebrew University in Jerusalem (Israel), and M.B.S. from the Ben Gurion University of the Negev in Israel.
Yoav began his tenure at TRIMA in January 2019 and is responsible for Operations, Quality Assurance, QC labs and Engineering.
Prior to joining TRIMA, Yoav served as CEO of a start-up bio-pharmaceutical company in Caesarea, Israel, advancing a Pre-IND submission of the company’s technology as well as a round B $7.5M capital fund-raising. Prior to that, Yoav held various positions at Perrigo Israel Pharmaceuticals (PIL). He started his career as a QC manager at Agis Industries (later acquired by PIL), moved to head the Analytical R&D, head of R&D projects management of Chemagis, led all inter-company development programs, ran the PIL major expansion program (a ca. US$50 million, five-year program that encompassed over 12,000 square meters buildings for industrial and utilities purposes) and finally managed the operations of the PIL Yeroham site in Israel, with over $300 million annual supply chain to the US, EU and Israel.
Yoav earned his B.Sc. in Chemistry and M.Sc. in Organic Chemistry from the Hebrew University in Jerusalem (Israel), and M.B.S. from the Ben Gurion University of the Negev in Israel.
-
Yotam Kaddar - VP Business Development
Yotam joined TRIMA’s BD in 2019 and was promoted to VP of Business Development at the beginning of 2021.
Prior to joining TRIMA, Yotam served as Senior Advisor at the Management Consulting and Strategy department of KPMG.
Prior to that Yotam filled a number of management positions including Finance Director at Anlit Ltd. (an innovative VMS developer and manufacturer) and Business Corporate Development Analyst at Maabarot products Ltd.
Yotam Holds a B.Sc. of Industrial Engineering and Management from the Ruppin Academic Center and an M.B.A from the Bar Ilan University.Yotam joined TRIMA’s BD in 2019 and was promoted to VP of Business Development at the beginning of 2021.
Prior to joining TRIMA, Yotam served as Senior Advisor at the Management Consulting and Strategy department of KPMG.
Prior to that Yotam filled a number of management positions including Finance Director at Anlit Ltd. (an innovative VMS developer and manufacturer) and Business Corporate Development Analyst at Maabarot products Ltd.
Yotam Holds a B.Sc. of Industrial Engineering and Management from the Ruppin Academic Center and an M.B.A from the Bar Ilan University. -
Ronen Bar-nir - CFO
Ronen joined TRIMA in 2014 as the Company’s CFO.
Prior to joining TRIMA, Ronen Filled the position of CFO of Kibbutz Maabarot and served on the Board of Directors of various public and private companies such as Maabarot Products Ltd., Trima Israel Pharmaceutical Products, Maabarot Ltd., Ambar Feed Institute and more.
Ronen earned his B.A. in Banking and Capital Markets from the Netanya Academic College (Israel).
Ronen joined TRIMA in 2014 as the Company’s CFO.
Prior to joining TRIMA, Ronen Filled the position of CFO of Kibbutz Maabarot and served on the Board of Directors of various public and private companies such as Maabarot Products Ltd., Trima Israel Pharmaceutical Products, Maabarot Ltd., Ambar Feed Institute and more.
Ronen earned his B.A. in Banking and Capital Markets from the Netanya Academic College (Israel).
-
Mariana Shwartzman - VP Research and Development
Mariana Leads Trima’s R&D activities since 2018 bringing to the position over 20 years of experience ranging across products (small molecules, biologics) and forms (solids, liquids, semi-solids and sterile).
Prior to joining TRIMA, Mariana headed the pharmaceutical “special” R&D operations in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Director of Pilot Pharma at Taro Pharmaceutical Industries Ltd. (NYSE: TARO).
Mariana holds a B.Tech degree in Biotechnology Engineering from ORT Braude College (Israel) and an M.B.A. from the Open University in Israel.
Mariana Leads Trima’s R&D activities since 2018 bringing to the position over 20 years of experience ranging across products (small molecules, biologics) and forms (solids, liquids, semi-solids and sterile).
Prior to joining TRIMA, Mariana headed the pharmaceutical “special” R&D operations in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Director of Pilot Pharma at Taro Pharmaceutical Industries Ltd. (NYSE: TARO).
Mariana holds a B.Tech degree in Biotechnology Engineering from ORT Braude College (Israel) and an M.B.A. from the Open University in Israel.
-
Gilad Eshel - VP Operations
Gilad joined TRIMA in 2006 as the Manager of the Packaging Department. He quickly advanced filling various management roles before becoming VP of Operations in 2014. Gilad is responsible for manufacturing, engineering, supply chain and logistics as well as the construction of Trima’s new manufacturing campus.
Prior to joining TRIMA, Gilad gained operational experience in various management positions in Materna – a Nestle company.
Gilad holds a degree in Industrial Engineering and Management, specializing in manufacturing, from the Ruppin Academic Center (Israel).
Gilad joined TRIMA in 2006 as the Manager of the Packaging Department. He quickly advanced filling various management roles before becoming VP of Operations in 2014. Gilad is responsible for manufacturing, engineering, supply chain and logistics as well as the construction of Trima’s new manufacturing campus.
Prior to joining TRIMA, Gilad gained operational experience in various management positions in Materna – a Nestle company.
Gilad holds a degree in Industrial Engineering and Management, specializing in manufacturing, from the Ruppin Academic Center (Israel).
-
Elinor Zonshine - VP Human Resources
Elinor joined the Human Resource Department at TRIMA in 2016, prior to being appointed to Human Resources Manager at the end of 2017.
Before joining TRIMA, Elinor served as Corporate Responsibility Manager at the Communications and External Relations Department of Harel Insurance Investments & Financial Services.
Elinor holds a B.A. in Middle Eastern and Geography studies and an M.A. in Public Policy from Tel-Aviv university.
Elinor joined the Human Resource Department at TRIMA in 2016, prior to being appointed to Human Resources Manager at the end of 2017.
Before joining TRIMA, Elinor served as Corporate Responsibility Manager at the Communications and External Relations Department of Harel Insurance Investments & Financial Services.
Elinor holds a B.A. in Middle Eastern and Geography studies and an M.A. in Public Policy from Tel-Aviv university.
-
Polina Kotler - VP Sales and Marketing
Polina joined Trima on January 1, 2020.
Prior to joining Trima Polina served as the CEO of Care for Life having previously filled the role of VP Sales and Marketing and Division Manager. Before that she filled the role of Head of Sales to Medical Institution in the Israeli subsidiary of Novartis Consumer Health, NCH Ltd.
Polina holds a B.A. in Medical Chemistry from the Bar Ilan University (Israel), an M.B.A. from the Tel Aviv University (Israel) and a Master in Digital Marketing from the New Media college (Israeli).
Polina joined Trima on January 1, 2020.
Prior to joining Trima Polina served as the CEO of Care for Life having previously filled the role of VP Sales and Marketing and Division Manager. Before that she filled the role of Head of Sales to Medical Institution in the Israeli subsidiary of Novartis Consumer Health, NCH Ltd.
Polina holds a B.A. in Medical Chemistry from the Bar Ilan University (Israel), an M.B.A. from the Tel Aviv University (Israel) and a Master in Digital Marketing from the New Media college (Israeli).
-
Prof. Gad Keren, M.D. - VP Medical
Prof. Keren is a professor of Cardiology at the Sackler school of Medicine and since 2002 until recently, was the Head of the department of Cardiology at the Tel Aviv Sourasky Medical Center and holds the Chaim Sheba Extraordinary Chair of Cardiology. He is currently the director of Cardiology at Assuta chain of Medical centers. Prof. Keren was also the president of the Israel Heart Society and served on multiple national and international Academic committees over the years and is the deputy editor of the IMAJ and Harefua Medical journals.
Prof. Keren has extensive experience in research from hemodynamics and cardiac imaging, to heart failure and mechanisms of disease progression. He has more than 400 scientific publications on record as well as multiple patents.
Prof. Keren serves on the Board of Directors of several companies and is an entrepreneur that initiated several start-up companies in Israel.
Prof. Keren holds a M.D. in Medicine a B.A in Philosophy both from Tel-Aviv University. Later, he continued his specialization and research in the USA at the Albert Einstein College of Medicine in NY and at the National Institutes of Health and at the Washington Hospital Center in Washington DC.
Prof. Keren is a professor of Cardiology at the Sackler school of Medicine and since 2002 until recently, was the Head of the department of Cardiology at the Tel Aviv Sourasky Medical Center and holds the Chaim Sheba Extraordinary Chair of Cardiology. He is currently the director of Cardiology at Assuta chain of Medical centers. Prof. Keren was also the president of the Israel Heart Society and served on multiple national and international Academic committees over the years and is the deputy editor of the IMAJ and Harefua Medical journals.
Prof. Keren has extensive experience in research from hemodynamics and cardiac imaging, to heart failure and mechanisms of disease progression. He has more than 400 scientific publications on record as well as multiple patents.
Prof. Keren serves on the Board of Directors of several companies and is an entrepreneur that initiated several start-up companies in Israel.
Prof. Keren holds a M.D. in Medicine a B.A in Philosophy both from Tel-Aviv University. Later, he continued his specialization and research in the USA at the Albert Einstein College of Medicine in NY and at the National Institutes of Health and at the Washington Hospital Center in Washington DC.
